1.Study on Material Basis and Action Mechanism of Chinese Formula Kai-Xin-San on Anti-depression via Regulation of Neurotrophic Factors
Cheng CAO ; Junyuan XIAO ; Mengqiu LIU ; Renjie HUANG ; Mingzhu QI ; Ziqiang ZHU ; Zhikang WANG ; Zhichun CHEN ; Jiani ZHENG ; Pei LIU ; Jinao DUAN ; Yue ZHU
World Science and Technology-Modernization of Traditional Chinese Medicine 2018;20(6):847-855
Objective: To observe the material basis and mechanism of action of Kai-Xin-San (KXS) in regulating antidepression of neurotrophic factors. Methods: KXS eluted by ethanol on macroporous resin was prepared. The antidepressive effect of different components was compared by tailing suspension test and forced swimming test of mice. The levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in hippocampus were determined by ELISA. The rat astrocyte glioma C6 cell line and the rat adrenal pheochromocytoma PC12 cell line were used to evaluate the effects of different ethanol elution sites on the expression of NGF and BDNF and the differentiation of PC12 cells.Results: All of the ethanol elution components from KXS exerted anti-depressive effects by shorting the immobile time of tailing suspension and forced swimming of mice and 70% ethanol elution components exerted best efficacy. This site also could increase expressions of NGF and BDNF on C6 glioma cell line. The 10% ethanol elution site had the strongest ability to promote PC12 cell differentiation. Ginsenosides were the main effectuve ingredients for promoting the expression of neurotrophic factors. Conclusion: Regulation of neurotrophic factors might be the prominent action mechanism of KXS exerting anti-depressive effects.
2.An excerpt of Asia-Pacific Association for the Study of the Liver guidelines on management of ascites in liver disease (2023)
Junyuan ZHU ; Xiao LIU ; Yawei CHENG ; Qingchen WANG ; Xiaochen LIU ; Yuhua ZHU ; Chunqing ZHANG
Journal of Clinical Hepatology 2024;40(1):37-41
Asia-Pacific Association for the Study of the Liver published the guidelines on management of ascites in liver disease in May 2023, which introduces the diagnosis, differential diagnosis, and treatment of ascites, hyponatremia, hepatic hydrothorax, and hepatorenal syndrome in patients with liver cirrhosis and acute-on-chronic liver failure. This article summarizes the main recommendations in the guidelines, so as to provide a reference for the treatment of ascites in patients with liver diseases in China.
3.Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2.
Guangshun ZHANG ; Junyuan CAO ; Yan CAI ; Yang LIU ; Yanli LI ; Peilin WANG ; Jiao GUO ; Xiaoying JIA ; Mengmeng ZHANG ; Gengfu XIAO ; Yu GUO ; Wei WANG
Protein & Cell 2019;10(2):137-142